22
2021-02
Completion of Patients’Recruitment for Proxalutamide’s COVID-19 Hospitalised Study
Suzhou, Feb.22, 2021--Kintor Pharmaceutical Limited is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients in Brazil completed the recruitment of 588 patients. The data of the clinical trial is expected to be available in March 2021.
18
2021-02
Suzhou, Feb.18, 2021--Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT90001 for a multi-regional phase II clinical trial for combination treatment of GT90001 and Nivolumab (Opdivo®) for the second-line treatment of advanced hepatocellular carcinoma (“HCC”) was approved by the Food and Drug Administration (the "US FDA") on February 11, 2021.
02
2021-02
Kintor’s GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
Suzhou, Feb.2, 2021--Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (the "NMPA") of China.
28
2021-01
Clinical Trial of Proxalutamide’s Trial of Hospitalized Covid-19 Patients Was Approved in Brazil
Suzhou, Jan 28, 2021--Kintor Pharmaceutical Limited is pleased to announce that the clinical trial of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil. The trial was accepted for accelerated review. We have received support from the Brazilian government in terms of medical resources allocation and expect to start with the patients recruitment over the coming weekend.
17
2021-01
Kintor Presented Results of GT90001 and Nivolumab Combination Therapy at ASCO GI 2021
Suzhou, Jan 17, 2021--Kintor Pharmaceutical Limited is pleased to release the positive data in phase II clinical trial of combination therapy of GT90001 and Nivolumab for the second line therapy of advanced hepatocellular carcinoma(“HCC”) in Taiwan (the “phase II clinical trial”) at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held between January 15 to 17, 2021.
10
2021-01
Kintor’s Preliminary Result of COVID-19 Trial in Female Patients
Suzhou, Jan 10, 2021--Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr. Andy Goren and Dr. Flávio Adsuara Cadegiani, shows promising results in the treatment of COVID-19 female outpatients.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn